## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

GENENTECH, INC. and CITY OF HOPE, )	
) Plaintiffs and Counterclaim Defendants, )	
v. )	
AMGEN INC.,	C.A. No. 18-924-CFC
Defendant and Counterclaim Plaintiff.	
GENENTECH, INC. and CITY OF HOPE, )	
) Plaintiffs and Counterclaim Defendants, )	
v. )	
) SAMSUNG BIOEPIS CO., LTD,	C.A. No. 18-1363-CFC
Defendant and Counterclaim Plaintiff.	
)	

# DECLARATION OF DR. HANSJÖRG HAUSER IN SUPPORT OF PLAINTIFFS' OPENING CLAIM CONSTRUCTION BRIEF

DOCKET

I, Dr. Hansjörg Hauser, declare as follows:

## I. Professional Experience and Qualifications

1. I am an expert in cell culture technology, which is the science of isolating cells from their natural environment and growing them in a controlled, artificial environment. In particular, I have expertise in cell culture processes used to manufacture biotherapeutics, such as therapeutic antibodies. I have over forty years of experience in molecular biology and have conducted significant research concerning the development of cell lines for protein expression. For the past two decades, I have served as editor of one of the leading textbooks in the field of cell culture technology for protein production: the "Mammalian Cell Biotechnology in Protein Production" textbook series (later retitled "Animal Cell Biotechnology: In Biologics Production").

2. I obtained a degree in Food Science from the Universität Stuttgart-Hohenheim, Germany in 1973, and a Ph.D. in Biology from the University of Konstanz, Konstanz, Germany in 1978.

3. After earning my Ph.D., I received postdoctoral training at Max Planck Institute for Molecular Genetics in Berlin, Germany from 1978 to 1980, and from the German Cancer Research Centre in Heidelberg, Germany in 1980. The Max Planck Institute is a leading research center that concentrates on understanding the function and regulation of the human genome. The German Cancer Research Centre is one of the largest biomedical research institutes in Germany. I completed a European Molecular Biology Organization ("EMBO") fellowship at the Medical Research Council National Institute for Medical Research at Mill Hill ("NIMR") in the United Kingdom in 1982. During my postdoctoral training and fellowship, my research focused on the molecular biology of mammalian cells with an emphasis on gene regulation. This work formed the basis for expression of individual genes in mammalian cells for production of biopharmaceuticals.

4. In 1981, I became a Staff Scientist at Helmholtz Centre for Infection Research (formerly Gesellschaft f. Biotechnologische Forschung (GBF)) in Braunschweig, Germany, and have worked there since. In 1986, I was promoted to Head of Research Group for Genetics of Eukaryotes. In 1994, I was promoted to Head of the Department of Gene Regulation and Differentiation. In 1995, I became Head of the Division of Molecular Biotechnology. In these positions, I conducted research and published extensively in the field of cell culture technology.

5. For example, I was the first investigator worldwide to express interferon-β in mammalian cells and to make production cells lines in BHK-21 and CHO cells. In further activities I collaborated with in-house researchers for the construction of cells expressing IL-2. Further work included the expression of potential biopharmaceuticals like antithrombin III, PDGF and various antibodies. Over the years, I have collaborated on issues related to cell culture with several of the world's leading biotechnology companies, including Merck KgaA, Ciba-Geigy (now known as Novartis), Boehringer Ingelheim, Roche and Bayer.

6. I have served as the chairman of the European Society of Animal Cell Technology (ESACT). ESACT was founded in 1976 to create a forum for the exchange of ideas on biological and engineering techniques to promote knowledge and the use of human and animal cells, *e.g.*, for the manufacturing of products. Members include scientists and engineers in academic, medical and industrial R&D and production at applied science institutions and universities, in the medical services, in industry, and in the political and regulatory bodies. I have also been involved with ACTIP (Animal Cell Culture Technology Industrial Platform) as an academic advisor from 1995 through 2017. I am also a guest professor at the University of Lisbon and a reviewer for scientific journals and research foundations in Germany, Europe, Israel, and the United States.

7. My curriculum vitae describes in greater detail my professional experience and qualifications, and includes a list of my numerous publications in the field. I have attached it as Exhibit 1.<sup>1</sup>

<sup>&</sup>lt;sup>1</sup> All exhibits cited herein are Exhibits to the Declaration of Nancy Lynn Schroeder, as described in the Exhibit List at the end of this declaration.

8. During the preceding five years, I have testified at deposition on behalf of Genentech in Case No. 18-cv-00574-RMB before the United States District Court for the District of New Jersey.

### **II.** Legal Standards and Instructions

9. I have been asked by counsel for Genentech to provide my opinion as to the construction of the claim language "following fermentation" and "pre-harvest [culture fluid]" in U.S. Patent No. 8,574,869 (the "Kao patent") (JA00000152-246). The purpose of this section of my declaration is to summarize the instructions I received from counsel in connection with preparing this opinion.

### A. Instructions Regarding Legal Concepts

### 1. The Person of Ordinary Skill

10. I have been asked to provide an opinion as to the person of ordinary skill in the art (or "POSA") to whom the invention disclosed and claimed in the Kao patent was directed. I understand that the POSA is a hypothetical person and can possess the skills and experience of multiple individuals working together as a team. I have been informed that factors that may be considered in determining the level of ordinary skill in the art may include: (1) the educational level of the inventors; (2) the types of problems encountered in the art; (3) prior art solutions to those problems; (4) rapidity with which innovations are made; (5) sophistication of the technology; and (6) the educational level of active workers in the field.

# **OCKET** LARM Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

# DOCKET



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

# **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

# **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

# API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

